当前位置: 首页 >> 检索结果
3682. Induction failure in granulomatosis with polyangiitis: a nationwide case-control study of risk factors and outcomes.
作者: Boris Sorin.;Michele Iudici.;Mary-Jane Guerry.;Maxime Samson.;Philip Bielefeld.;Thibault Maillet.;Mathilde Nouvier.;Alexandre Karras.;Lara Meyer.;Christian Lavigne.;Alexis Régent.;Cécile-Audrey Durel.;Marc Fabre.;Pierre Charles.;Quentin Raimbourg.;Aurélia Lanteri.;Grégory Pugnet.;Frédéric Rivière.;Marc Pineton de Chambrun.;Patrice Cacoub.;Guillaume Le Guenno.;Pierre Jourdain.;Arsène Mekinian.;Romain Paule.;Jérémie Dion.;Paul Legendre.;Pascal Cohen.;Loïc Guillevin.;Xavier Puéchal.;Benjamin Terrier.
来源: Rheumatology (Oxford). 2023年62卷11期3662-3671页
To identify characteristics of granulomatosis with polyangiitis (GPA) associated with induction failure, describe salvage therapies and their efficacy.
3683. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
作者: Rita N Cunha.;Liliana Saraiva.;Diogo Jesus.;Andrea Doria.;José P da Silva.;Luís S Inês.
来源: Rheumatology (Oxford). 2023年62卷11期3627-3635页
The treatment target in SLE should be maintained stable by preventing flares. The objectives were to identify predictors of flare in patients attaining lupus low disease activity state (LLDAS), and to assess whether remission with no glucocorticoids is associated with lower risk of flares.
3685. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study.
作者: Grace Qian.;Xiaosong Wang.;Naomi J Patel.;Yumeko Kawano.;Xiaoqing Fu.;Claire E Cook.;Kathleen M M Vanni.;Emily N Kowalski.;Emily P Banasiak.;Katarina J Bade.;Shruthi Srivatsan.;Zachary K Williams.;Derrick J Todd.;Michael E Weinblatt.;Zachary S Wallace.;Jeffrey A Sparks.
来源: Lancet Rheumatol. 2023年5卷3期e139-e150页
Some patients with systemic autoimmune rheumatic disease and immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS-CoV-2 treatments on COVID-19 outcomes among patients with systemic autoimmune rheumatic disease is unclear. We aimed to evaluate temporal trends, severe outcomes, and COVID-19 rebound among patients with systemic autoimmune rheumatic disease and COVID-19 who received outpatient SARS-CoV-2 treatment compared with those who did not receive outpatient treatment.
3686. Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment-specific patient-reported outcome measure.
作者: Susan Bridgewater.;Michael A Shepherd.;Jill Dawson.;Pamela Richards.;Christine Silverthorne.;Mwidimi Ndosi.;Celia Almeida.;Rachel J Black.;Jonathan T L Cheah.;Emma Dures.;Nilasha Ghosh.;Elizabeth A Hoon.;Suellen Lyne.;Iris Navarro-Millan.;Diyu Pearce-Fisher.;Carlee Ruediger.;Joanna Tieu.;Kevin Yip.;Sarah L Mackie.;Susan Goodman.;Catherine Hill.;Joanna C Robson.
来源: Rheumatology (Oxford). 2023年62卷11期3565-3575页
Glucocorticoids (GCs) ('steroids') are used to treat rheumatic diseases but adverse effects are common. We aimed to explore the impact of GC therapy on health-related quality of life (HRQoL), to inform the development of a treatment-specific patient-reported outcome measure (PROM) for use in clinical trials and practice.
3688. The impact of health literacy: associations with disease activity and medication prescription in patients with rheumatoid arthritis.
作者: Anne Gorter.;Mark M Bakker.;Peter M Ten Klooster.;Annelies Boonen.;Harald E Vonkeman.
来源: Rheumatology (Oxford). 2023年62卷10期3409-3415页
The aim of this study was to explore the longitudinal associations between health literacy profiles and disease activity and medication prescription in patients with RA.
3689. Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data.
作者: Christopher J Edwards.;Julie Mount.;Alexandra Meeks.;Tania Gulati.;Liliana Zaremba-Pechmann.;Mohamed Sheesh.;Esbjörn Larsson.;Elaine Dennison.
来源: Rheumatology (Oxford). 2023年62卷10期3400-3408页
To describe selected baseline characteristics, continuation with baricitinib and disease activity over time in patients initiating treatment with baricitinib in a UK real-world rheumatology setting.
3690. Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration.
作者: Kazuki M Matsuda.;Ayumi Yoshizaki.;Ai Kuzumi.;Satoshi Toyama.;Kentaro Awaji.;Tomomi Miyake.;Shinichi Sato.
来源: Rheumatology (Oxford). 2023年62卷9期3139-3145页
SSc is an autoimmune disease characterized by excessive fibrosis in multiple organs, including the gastrointestinal (GI) tract. GI symptoms of SSc such as intestinal pseudo-obstruction (IPO) are often refractory to conventional intervention and can result in longer in-hospital stay or even increased mortality. We aimed to summarize the insights to date regarding the efficacy of IVIG against GI symptoms of SSc to unveil what we should focus on in future studies.
3692. Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application.
作者: Andrei Barbulescu.;Arvid Sjölander.;Bénédicte Delcoigne.;Johan Askling.;Thomas Frisell.
来源: Rheumatology (Oxford). 2023年62卷10期3391-3399页
Observational studies have reported an increased risk of infections associated with glucocorticoids in RA, not supported by evidence from randomized controlled trials. Inappropriately accommodating time-varying exposure and confounding in observational studies might explain the conflicting results. Therefore, we compared the incidence of serious infections between different oral glucocorticoid dose patterns over three years in a prospective inception cohort, adjusting for time-varying confounders in marginal structural models.
3694. Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis.
作者: Andriko Palmowski.;Sabrina M Nielsen.;Zhivana Boyadzhieva.;Abelina Schneider.;Anne Pankow.;Linda Hartman.;José A P Da Silva.;John Kirwan.;Siegfried Wassenberg.;Christian Dejaco.;Robin Christensen.;Maarten Boers.;Frank Buttgereit.
来源: Rheumatology (Oxford). 2023年62卷8期2652-2660页
The aim of this study was to assess the safety and efficacy of long-term low-dose glucocorticoids (GCs) in RA.
3695. Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.
作者: Arno W R Van Kuijk.;Mike T Nurmohamed.;Stefan Siebert.;Paul Bergmans.;Kurt de Vlam.;Elisa Gremese.;Beatriz Joven-Ibáñez.;T V Korotaeva.;Frederic Lavie.;Mohamed Sharaf.;Wim Noël.;Elke Theander.;Josef S Smolen.;Laure Gossec.;Irene E van der Horst-Bruinsma.
来源: Rheumatology (Oxford). 2023年62卷10期3382-3390页
Investigate effects of gender on disease characteristics and treatment impact in patients with PsA.
3696. Clinical characteristics of early-onset paediatric systemic lupus erythematosus in a single centre in China.
作者: Yipei Hou.;Li Wang.;Chong Luo.;Wenjing Tang.;Rongxin Dai.;Yunfei An.;Xuemei Tang.
来源: Rheumatology (Oxford). 2023年62卷10期3373-3381页
We sought to investigate the sex distribution, clinical presentations, disease outcomes and genetic background of early-onset paediatric SLE (eo-pSLE) in a single centre in China to help enable early diagnosis and timely treatment.
3697. Anti-dsDNA IgE induces IL-4 production from basophils, potentially involved in B-cell differentiation in systemic lupus erythematosus.
作者: Sho Fujimoto.;Yojiro Arinobu.;Kohta Miyawaki.;Masahiro Ayano.;Hiroki Mitoma.;Yasutaka Kimoto.;Nobuyuki Ono.;Koichi Akashi.;Takahiko Horiuchi.;Hiroaki Niiro.
来源: Rheumatology (Oxford). 2023年62卷10期3480-3489页
Recently, the involvement of basophils and IgE-type autoantibodies in the pathogenesis of SLE has been elucidated using mouse models; however, few studies have been conducted in humans. In this study, the role of basophils and anti-double-stranded DNA (dsDNA) IgE in SLE was examined using human samples.
3700. CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum.
作者: David Turgeon.;Volodko Bakowsky.;Corisande Baldwin.;David A Cabral.;Marie Clements-Baker.;Alison Clifford.;Jan Willem Cohen Tervaert.;Natasha Dehghan.;Daniel Ennis.;Leilani Famorca.;Aurore Fifi-Mah.;Louis-Philippe Girard.;Frédéric Lefebvre.;Patrick Liang.;Jean-Paul Makhzoum.;David Massicotte-Azarniouch.;Arielle Mendel.;Nataliya Milman.;Heather N Reich.;David B Robinson.;Carolyn Ross.;Dax G Rumsey.;Medha Soowamber.;Tanveer E Towheed.;Judith Trudeau.;Marinka Twilt.;Elaine Yacyshyn.;Gozde K Yardimci.;Nader Khalidi.;Lillian Barra.;Christian Pagnoux.
来源: Rheumatology (Oxford). 2023年62卷8期2646-2651页
In 2020, the Canadian Vasculitis Research Network (CanVasc) published their updated recommendations for the management of ANCA-associated vasculitides (AAV). The current addendum provides further recommendations regarding the use of avacopan in AAV based on a review of newly available evidence.
|